Shares of Chinese pharmaceutical companies decline following reports of potential regulatory actions from former President Trump.
Chinese drugmaker stocks experienced a decline after reports emerged about possible curbs being considered by former U.S. President Donald Trump. The market reaction reflects investor concerns about future regulatory challenges affecting the sector.